TABLE 2.
Drug susceptibility test results of MABS patientsa
| MABS (86) |
Mab (46) |
Mma (40) |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Antibiotic | Susceptible | Intermediate | Resistant | Susceptible | Intermediate | Resistant | Susceptible | Intermediate | Resistant |
| Clarithromycin | 39 (45.3) | 1 (1.2) | 46 (53.5) | 7 (15.2) | 1 (2.2) | 38 (82.6) | 32 (80.0) | 0 (0.0) | 8 (20.0) |
| Azithromycin | 29 (33.7) | 5 (5.8) | 52 (60.5) | 4 (8.7) | 0 (0.0) | 42 (91.3) | 25 (62.5) | 5 (12.5) | 10 (25.0) |
| Amikacin | 80 (93.0) | 3 (3.5) | 3 (3.5) | 42 (91.3) | 1 (2.2) | 3 (6.5) | 38 (95.0) | 2 (5.0) | 0 (0.0) |
| Tobramycin | 0 (0.0) | 8 (9.3) | 78 (90.7) | 0 (0.0) | 7 (15.2) | 39 (84.8) | 0 (0.0) | 1 (2.5) | 39 (97.5) |
| Imipenem | 22 (25.6) | 56 (65.1) | 8 (9.3) | 12 (26.1) | 29 (63.0) | 5 (10.9) | 10 (25.0) | 27 (67.5) | 3 (7.5) |
| Meropenem | 1 (1.2) | 4 (4.7) | 81 (94.2) | 1 (2.2) | 4 (8.7) | 41 (89.1) | 0 (0.0) | 0 (0.0) | 40 (100) |
| Faropenem | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Levofloxacin | 0 (0.0) | 1 (1.2) | 85 (98.8) | 0 (0.0) | 0 (0.0) | 46 (100) | 0 (0.0) | 1 (2.5) | 39 (97.5) |
| Moxifloxacin | 5 (5.8) | 13 (15.1) | 68 (79.1) | 2 (4.3) | 11 (23.9) | 33 (71.7) | 3 (7.5) | 2 (5.0) | 35 (87.5) |
| Sitafloxacin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Trimethoprim/sulfamethoxazole | 2 (2.3) | N/A | 84 (97.7) | 1 (2.2) | N/A | 45 (97.8) | 1 (2.5) | N/A | 39 (97.5) |
| Doxycycline | 0 (0.0) | 3 (3.5) | 83 (96.5) | 0 (0.0) | 0 (0.0) | 46 (100) | 0 (0.0) | 3 (7.5) | 37 (92.5) |
| Linezolid | 48 (55.8) | 27 (31.4) | 11 (12.8) | 27 (58.7) | 12 (26.1) | 7 (15.2) | 21 (52.5) | 15 (37.5) | 4 (10.0) |
| Clofazimine | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
a
Data are presented as n (%). MABS, Mycobacterium abscessus; Mab, Mycobacterium abscessus subsp. abscessus; Mma, Mycobacterium abcessus subsp. massiliense; N/A, not applicable.